IN2014MN01548A - - Google Patents
Info
- Publication number
- IN2014MN01548A IN2014MN01548A IN1548MUN2014A IN2014MN01548A IN 2014MN01548 A IN2014MN01548 A IN 2014MN01548A IN 1548MUN2014 A IN1548MUN2014 A IN 1548MUN2014A IN 2014MN01548 A IN2014MN01548 A IN 2014MN01548A
- Authority
- IN
- India
- Prior art keywords
- compounds
- disclosed
- methods
- agents
- host
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1548MUN2014 IN2014MN01548A (de) | 2012-02-10 | 2013-02-09 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN147KO2012 | 2012-02-10 | ||
| IN1017KO2012 | 2012-09-04 | ||
| PCT/IB2013/051077 WO2013118102A1 (en) | 2012-02-10 | 2013-02-09 | Antiviral compounds with a heterotricycle moiety |
| IN1548MUN2014 IN2014MN01548A (de) | 2012-02-10 | 2013-02-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01548A true IN2014MN01548A (de) | 2015-05-08 |
Family
ID=54259033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1547MUN2014 IN2014MN01547A (de) | 2012-02-10 | 2013-02-08 | |
| IN1548MUN2014 IN2014MN01548A (de) | 2012-02-10 | 2013-02-09 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1547MUN2014 IN2014MN01547A (de) | 2012-02-10 | 2013-02-08 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9073943B2 (de) |
| EP (2) | EP2812326A1 (de) |
| JP (1) | JP6034883B2 (de) |
| KR (1) | KR20140129034A (de) |
| CN (1) | CN104136433B (de) |
| AU (2) | AU2013217224B2 (de) |
| BR (1) | BR112014019584A8 (de) |
| CA (2) | CA2862755A1 (de) |
| IN (2) | IN2014MN01547A (de) |
| MX (1) | MX2014009546A (de) |
| NZ (2) | NZ628515A (de) |
| SG (2) | SG11201404475TA (de) |
| WO (2) | WO2013118097A1 (de) |
| ZA (1) | ZA201405490B (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013007106A1 (zh) | 2011-07-09 | 2013-01-17 | 广东东阳光药业有限公司 | 作为丙型肝炎病毒抑制剂的螺环化合物 |
| CA2862755A1 (en) | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| EP3021845A1 (de) | 2013-07-17 | 2016-05-25 | Bristol-Myers Squibb Company | Kombinationen mit biphenylderivaten zur verwendung bei der behandlung von hcv |
| CN104725365B (zh) * | 2013-12-23 | 2019-02-26 | 南京圣和药业股份有限公司 | 丙型肝炎病毒抑制剂及其应用 |
| WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| KR20170115940A (ko) * | 2016-04-08 | 2017-10-18 | 롬엔드하스전자재료코리아유한회사 | 유기 전계 발광 화합물 및 이를 포함하는 유기 전계 발광 소자 |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| EP3454856A4 (de) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | Heterocyclische degronimere für zielproteinabbau |
| UY38705A (es) * | 2019-05-23 | 2020-12-31 | Irbm S P A | Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b |
| CN114605310B (zh) * | 2022-04-09 | 2024-05-07 | 都创(上海)医药科技股份有限公司 | 一种氮杂五元环并三元环羧酸酯衍生物及其盐的合成方法 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| AU2003261434A1 (en) | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
| EP1650202A4 (de) | 2003-07-31 | 2007-04-04 | Taisho Pharmaceutical Co Ltd | 4,5-dihydronaphtho[1,2-b]thiophenderivat |
| EP1670744B9 (de) | 2003-09-19 | 2012-09-05 | Janssen Pharmaceutica NV | 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga |
| BRPI0416287A (pt) | 2003-11-07 | 2007-01-23 | Hoffmann La Roche | compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização |
| GB0421908D0 (en) | 2004-10-01 | 2004-11-03 | Angeletti P Ist Richerche Bio | New uses |
| GB0501964D0 (en) | 2005-01-31 | 2005-03-09 | Arrow Therapeutics Ltd | Chemical compounds |
| US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| AU2006290442B2 (en) | 2005-09-16 | 2010-07-29 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis C |
| WO2007070600A2 (en) | 2005-12-12 | 2007-06-21 | Genelabs Technologies, Inc. | N-(5-membered heteroaromatic ring)-amido anti-viral compounds |
| EP1976829A2 (de) | 2005-12-12 | 2008-10-08 | Genelabs Technologies, Inc. | N-(6-gliedriger aromatischer ring)-amidoverbindungen mit antiviraler wirkung |
| WO2007082554A1 (en) | 2006-01-23 | 2007-07-26 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Modulators of hcv replication |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2680507A1 (en) | 2006-10-13 | 2008-04-24 | Xtl Biopharmaceuticals Ltd. | Compounds and methods for treatment of hcv |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2097405A2 (de) | 2006-11-21 | 2009-09-09 | Smithkline Beecham Corporation | Antivirale verbindungen |
| WO2008064218A2 (en) | 2006-11-21 | 2008-05-29 | Smithkline Beecham Corporation | Amido anti-viral compounds |
| US7521444B2 (en) | 2007-03-14 | 2009-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW200906826A (en) | 2007-06-12 | 2009-02-16 | Genelabs Tech Inc | Anti-viral inhibitors and methods of use |
| PT2170888E (pt) | 2007-06-29 | 2015-08-21 | Gilead Sciences Inc | Purina derivados e sua utilização como moduladores de recetor de tipo toll 7 |
| US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
| WO2009034390A1 (en) | 2007-09-14 | 2009-03-19 | Arrow Therapeutics Limited | Heterocyclic derivatives and their use in treating hepatitis c |
| CN101868452B (zh) | 2007-10-10 | 2014-08-06 | 诺华股份有限公司 | 螺环吡咯烷类与其对抗hcv和hiv感染的应用 |
| JP5314053B2 (ja) | 2008-02-12 | 2013-10-16 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎ウイルス阻害剤 |
| US8093243B2 (en) | 2008-02-12 | 2012-01-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR101492672B1 (ko) | 2008-02-13 | 2015-02-16 | 브리스톨-마이어스 스큅 컴퍼니 | Ｃ형 간염 바이러스 억제제로서의 이미다졸릴 바이페닐 이미다졸 |
| US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| NZ588400A (en) | 2008-04-23 | 2012-08-31 | Gilead Sciences Inc | 1'-substituted carba-nucleoside analogs for antiviral treatment |
| US8133884B2 (en) | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8198449B2 (en) | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US20110217265A1 (en) | 2008-09-23 | 2011-09-08 | Glenn Jeffrey S | Screening for Inhibitors of HCV Amphipathic Helix (AH) Function |
| KR20110098779A (ko) * | 2008-12-03 | 2011-09-01 | 프레시디오 파마슈티칼스, 인코포레이티드 | Ｈｃｖ ｎｓ5ａ의 억제제 |
| PE20120257A1 (es) | 2009-02-10 | 2012-03-29 | Gilead Sciences Inc | Analogos carba-nucleosidicos para tratamiento antiviral |
| TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| WO2010096462A1 (en) | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
| EP2398474A4 (de) | 2009-02-23 | 2012-12-05 | Presidio Pharmaceuticals Inc | Hcv-ns5a-shemmer |
| US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| SG174883A1 (en) | 2009-03-27 | 2011-11-28 | Presidio Pharmaceuticals Inc | Fused ring inhibitors of hepatitis c |
| KR20130140219A (ko) | 2009-03-27 | 2013-12-23 | 머크 샤프 앤드 돔 코포레이션 | Ｃ형 간염 바이러스 복제의 억제제 |
| EP2410841A4 (de) | 2009-03-27 | 2012-10-24 | Presidio Pharmaceuticals Inc | Substituierte bicyclische hcv-hemmer |
| US20110237636A1 (en) | 2009-03-30 | 2011-09-29 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| RS56654B8 (sr) | 2009-05-13 | 2021-06-30 | Gilead Pharmasset Llc | Antiviralna jedinjenja |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| WO2010148006A1 (en) | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| AU2010280711A1 (en) | 2009-08-07 | 2012-02-09 | Janssen Sciences Ireland Uc | Phenyl ethynyl derivatives as hepatitis C virus inhibitors |
| US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| EP2475254A4 (de) | 2009-09-11 | 2013-05-22 | Enanta Pharm Inc | Hemmer des hepatitis-c-virus |
| US8415374B2 (en) | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2013515068A (ja) | 2009-12-22 | 2013-05-02 | メルク・シャープ・アンド・ドーム・コーポレーション | ウイルス性疾患の治療のための縮合三環式化合物およびその使用方法 |
| US20130072523A1 (en) | 2009-12-24 | 2013-03-21 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011106929A1 (en) | 2010-03-02 | 2011-09-09 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus ns5b polymerase |
| TW201136919A (en) | 2010-03-02 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | Inhibitors of hepatitis C virus NS5B polymerase |
| JP2013521279A (ja) | 2010-03-04 | 2013-06-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｈｃｖ複製の阻害剤としての医薬併用剤 |
| SG183526A1 (en) | 2010-03-09 | 2012-09-27 | Merck Sharp & Dohme | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
| WO2011127350A1 (en) | 2010-04-09 | 2011-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2011151652A1 (en) | 2010-06-03 | 2011-12-08 | Arrow Therapeutics Limited | Benzodiazepine compounds useful for the treatment of hepatitis c |
| WO2011151651A1 (en) | 2010-06-03 | 2011-12-08 | Arrow Therapeutics Limited | Benzodiazepine compounds useful for the treatment of hepatitis c |
| EP2575819A4 (de) | 2010-06-04 | 2013-11-27 | Enanta Pharm Inc | Hemmer des hepatitis-c-virus |
| CA2802067A1 (en) | 2010-06-09 | 2011-12-15 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a protein |
| AU2011286276A1 (en) | 2010-07-26 | 2013-01-24 | Merck Sharp & Dohme Corp. | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
| EA022127B1 (ru) | 2010-08-04 | 2015-11-30 | Бристол-Майерс Сквибб Компани | Ингибиторы вируса гепатита с |
| US8697704B2 (en) | 2010-08-12 | 2014-04-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CN103153978A (zh) | 2010-08-17 | 2013-06-12 | 沃泰克斯药物股份有限公司 | 用于治疗或预防黄病毒科病毒感染的化合物和方法 |
| CN103249730A (zh) | 2010-09-24 | 2013-08-14 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
| EP2621931A4 (de) | 2010-09-29 | 2014-03-19 | Merck Sharp & Dohme | Tetrazyklische indolderivate zur behandlung von hepatitis-c-virus-infektionen |
| EP2621932A4 (de) | 2010-09-29 | 2014-03-26 | Merck Sharp & Dohme | Tetrazyklische heterozyklus-verbindungen zur behandlung von hepatitis-c-virus-infektionen |
| KR20190012271A (ko) | 2010-11-17 | 2019-02-08 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
| CA2862755A1 (en) | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
-
2013
- 2013-02-08 CA CA2862755A patent/CA2862755A1/en not_active Abandoned
- 2013-02-08 US US14/375,534 patent/US9073943B2/en not_active Expired - Fee Related
- 2013-02-08 IN IN1547MUN2014 patent/IN2014MN01547A/en unknown
- 2013-02-08 WO PCT/IB2013/051062 patent/WO2013118097A1/en active Application Filing
- 2013-02-08 NZ NZ628515A patent/NZ628515A/en not_active IP Right Cessation
- 2013-02-08 SG SG11201404475TA patent/SG11201404475TA/en unknown
- 2013-02-08 EP EP13715002.5A patent/EP2812326A1/de not_active Ceased
- 2013-02-08 AU AU2013217224A patent/AU2013217224B2/en not_active Expired - Fee Related
- 2013-02-09 IN IN1548MUN2014 patent/IN2014MN01548A/en unknown
- 2013-02-09 CN CN201380008883.4A patent/CN104136433B/zh not_active Expired - Fee Related
- 2013-02-09 AU AU2013217229A patent/AU2013217229B2/en not_active Expired - Fee Related
- 2013-02-09 SG SG11201404365SA patent/SG11201404365SA/en unknown
- 2013-02-09 US US14/375,530 patent/US9073942B2/en not_active Expired - Fee Related
- 2013-02-09 CA CA2862330A patent/CA2862330A1/en not_active Abandoned
- 2013-02-09 NZ NZ628445A patent/NZ628445A/en not_active IP Right Cessation
- 2013-02-09 MX MX2014009546A patent/MX2014009546A/es unknown
- 2013-02-09 JP JP2014556185A patent/JP6034883B2/ja not_active Expired - Fee Related
- 2013-02-09 EP EP13708912.4A patent/EP2812327A1/de not_active Withdrawn
- 2013-02-09 BR BR112014019584A patent/BR112014019584A8/pt active Search and Examination
- 2013-02-09 WO PCT/IB2013/051077 patent/WO2013118102A1/en active Application Filing
- 2013-02-09 KR KR20147023151A patent/KR20140129034A/ko not_active Application Discontinuation
-
2014
- 2014-07-25 ZA ZA2014/05490A patent/ZA201405490B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014019584A2 (de) | 2017-06-20 |
| CN104136433A (zh) | 2014-11-05 |
| NZ628445A (en) | 2016-05-27 |
| AU2013217224B2 (en) | 2017-04-06 |
| SG11201404365SA (en) | 2014-10-30 |
| AU2013217224A1 (en) | 2014-08-21 |
| NZ628515A (en) | 2016-06-24 |
| US20150010505A1 (en) | 2015-01-08 |
| KR20140129034A (ko) | 2014-11-06 |
| US9073942B2 (en) | 2015-07-07 |
| JP2015510512A (ja) | 2015-04-09 |
| ZA201405490B (en) | 2015-10-28 |
| AU2013217229B2 (en) | 2017-03-02 |
| BR112014019584A8 (pt) | 2017-07-11 |
| US9073943B2 (en) | 2015-07-07 |
| AU2013217229A1 (en) | 2014-08-21 |
| US20150010504A1 (en) | 2015-01-08 |
| IN2014MN01547A (de) | 2015-05-08 |
| WO2013118097A1 (en) | 2013-08-15 |
| EP2812326A1 (de) | 2014-12-17 |
| SG11201404475TA (en) | 2014-08-28 |
| CN104136433B (zh) | 2016-05-04 |
| EP2812327A1 (de) | 2014-12-17 |
| MX2014009546A (es) | 2015-10-29 |
| CA2862330A1 (en) | 2013-08-15 |
| CA2862755A1 (en) | 2013-08-15 |
| WO2013118102A1 (en) | 2013-08-15 |
| JP6034883B2 (ja) | 2016-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01548A (de) | ||
| PH12014502739A1 (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| NZ724503A (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| NZ703066A (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| NZ703064A (en) | Inhibitors of hepatitis c virus | |
| MX2012008221A (es) | Inhibidores de virus flaviviridae. | |
| MX2020003055A (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
| MX2012008211A (es) | Inhibidores de virus flaviviridae. | |
| MX2013006475A (es) | Inhibidores macrociclicos de virus flaviviridae. | |
| EA026667B9 (ru) | Фармацевтическая композиция для лечения вируса гепатита с | |
| NZ748966A (en) | Functionalized benzamide derivatives as antiviral agents against hbv infection | |
| MX2012000959A (es) | Inhibidores de los virus flaviviridae. | |
| CL2011002830A1 (es) | Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c. | |
| EA201301158A1 (ru) | Противовирусные соединения | |
| NZ631726A (en) | Therapeutic compounds for the treatment of viral infections | |
| IN2012DN01855A (de) | ||
| JO3281B1 (ar) | مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي | |
| PH12015501560A1 (en) | Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases | |
| MX2015013649A (es) | Inhibidores novedosos de la replicación viral. | |
| WO2014116772A3 (en) | Squaric derivatives for the treatment of hepatitis c | |
| IN2011CH03893A (de) | ||
| TN2013000335A1 (en) | Hepatitis c virus inhibitors |